Biology of T Cells - Part B, Volume 342, the latest release in the International Review of Cell and Molecular Biology series, offers an overview of the major molecular and cellular aspects of T-cell biology and their links to human pathophysiology. Chapters in this release include Metabolism of T lymphocytes in health and disease, T lymphocytes and autoimmunity, Cancer immunosurveillance by T cells, T lymphocytes as targets in viral disorders, Molecular mechanisms underlying pharmacological immunosuppression, T lymphocyte-based immunotherapeutics, In silico methods to analyze T cell biology, and Engineering Platforms for T Cell Modulation.
Biology of T Cells - Part B jetzt bestellen!
Zielgruppe
<p>The book (which consists of two parts, part A and part B) is equally addressed to expert investigators who may wish to expand their knowledge on the biology of T cells, and to newcomers to this exciting and rapidly expanding area of research.</p>
Weitere Infos & Material
1. Metabolism of T lymphocytes in health and disease Timo Gaber 2. T lymphocytes and autoimmunity Uqba Khan 3. Cancer immunosurveillance by T cells Arnold Han 4. T lymphocytes as targets in viral disorders Anne Monette 5. Molecular mechanisms underlying pharmacological immunosuppression Nicolas Pallet and Marie-Anne Loirot 6. T lymphocyte-based immunotherapeutics Saman Maleki Vareki 7. In silico methods to analyze T cell biology Sebastiano Battaglia 8. Engineering Platforms for T Cell Modulation Jonathan Schneck
Rudqvist, Nils-Petter
Nils-Petter Rudqvist received his M.Sc. (Physics, 2009) and Ph.D. (Medical Science, 2015) from the University of Gothenburg, Sweden. He decided to pursue an academic career and continue with his postdoctoral training in US. He first joined the Center for Radiological Research at Columbia University in New York where he studied gene signatures of radiation exposure. He then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Demaria. His current research is focused on investigating which neoantigens are key targets of the radiation-induced anti-tumor T cell response in mice and in patients treated with radiotherapy and immune checkpoint blockade. He recently demonstrated in a mouse model that radiation therapy diversifies the TCR repertoire of tumor infiltrating lymphocytes, an effect crucial for its synergy with immune checkpoint blockade treatment. Nils-Petter has also defined unique patters of expansion of TCR clonotypes in patients who respond or not to treatment with radiotherapy and ipilimumab. He has published 20 articles in peer-reviewed scientific journals and 60+ scientific conference abstracts.
